



(51) International Patent Classification:

A61K 47/18 (2006.01) A61K 47/68 (2017.01)

A61K 47/26 (2006.01) A61K 9/08 (2006.01)

A61K 38/18 (2006.01) A61K 9/19 (2006.01)

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2022/077968

(22) International Filing Date:

12 October 2022 (12.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/255,286 13 October 2021 (13.10.2021) US

(71) Applicant: AKERO THERAPEUTICS, INC. [US/US];

601 Gateway Blvd., Suite 350, South San Francisco, CA 94080 (US).

(72) Inventors: DIMITROVA, Mariana, N.; 601 Gateway Blvd., Suite 350, South San Francisco, CA 94080 (US).

ROLPH, Timothy, P.; 601 Gateway Blvd., Suite 350, South San Francisco, CA 94080 (US).

(74) Agent: KISSLING, Heather, R.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

(54) Title: PHARMACEUTICAL COMPOSITIONS OF EFRUXIFERMIN

(57) Abstract: The disclosure provides pharmaceutical compositions comprising Efruxifermin, processes for preparing lyophilized compositions, and methods of use for treating nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFL), alcoholic steatohepatitis (ASH), alcoholic liver disease (ALD) or alcoholic fatty liver disease (AFL), type 2 diabetes, obesity, hypertriglyceridemia, dyslipidemia, protein misfolding disease, alcohol-related and other cravings or addictions, reversing liver cirrhosis or reducing fibrosis associated with NASH, ASH, ALD AFL, or protein misfolding disease, normalizing liver fat content, reducing elevated blood glucose, increasing insulin sensitivity, and/or reducing uric acid levels.



PCT

(PCT Rule 92*bis*.1 and
Administrative Instructions, Section 422)

KISSLING, Heather, R.
Marshall, Gerstein & Borun LLP
233 S. Wacker Drive
6300 Willis Tower
Chicago, IL 60606
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (day/month/year) 09 April 2024 (09.04.2024)			
Applicant's or agent's file reference 32990/50011/PC		IMPORTANT NOTIFICATION	
International application No. PCT/US2022/077968		International filing date (day/month/year) 12 October 2022 (12.10.2022)	
1. The following indications appeared on record concerning: ☐ the applicant ☒ the inventor ☐ the agent ☐ the common representative			
Name and Address		State of Nationality	State of Residence
		Telephone No.	
		Facsimile No.	
		E-mail address	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning: ☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence			
Name and Address BOSTICK, James c/o Coriolis Pharma Research GmbH Fraunhoferstr. 18B 82152 Martinsried GERMANY		State of Nationality	State of Residence
		Telephone No.	
		Facsimile No.	
		E-mail address ☐ Notifications by e-mail authorized	
3. Further observations, if necessary: The person identified in Box 2 has been added as inventor only.			
4. A copy of this notification has been sent to: ☒ the receiving Office ☐ the International Preliminary Examining Authority ☒ the International Searching Authority ☒ the designated Offices concerned ☐ the Authority(ies) specified for supplementary search ☐ the elected Offices concerned ☐ other: ☐			
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland		Authorized officer Blanc Veronique e-mail pct.team9@wipo.int Telephone No. +41 22 338 74 09	

PCT

(PCT Rule 92*bis*.1 and
Administrative Instructions, Section 422)

KISSLING, Heather, R.
Marshall, Gerstein & Borun LLP
233 S. Wacker Drive
6300 Willis Tower
Chicago, IL 60606
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (<i>day/month/year</i>) 09 April 2024 (09.04.2024)			
Applicant's or agent's file reference 32990/50011/PC		IMPORTANT NOTIFICATION	
International application No. PCT/US2022/077968		International filing date (<i>day/month/year</i>) 12 October 2022 (12.10.2022)	
1. The following indications appeared on record concerning: ☐ the applicant ☒ the inventor ☐ the agent ☐ the common representative			
Name and Address		State of Nationality	State of Residence
		Telephone No.	
		Facsimile No.	
		E-mail address	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning: ☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence			
Name and Address EISELE, Simon c/o Coriolis Pharma Research GmbH Fraunhoferstr. 18B 82152 Martinsried GERMANY		State of Nationality	State of Residence
		Telephone No.	
		Facsimile No.	
		E-mail address ☐ Notifications by e-mail authorized	
3. Further observations, if necessary: The person identified in Box 2 has been added as inventor only.			
4. A copy of this notification has been sent to: ☒ the receiving Office ☐ the International Preliminary Examining Authority ☒ the International Searching Authority ☒ the designated Offices concerned ☐ the Authority(ies) specified for supplementary search ☐ the elected Offices concerned ☐ other:			
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland		Authorized officer Blanc Veronique e-mail pct.team9@wipo.int Telephone No. +41 22 338 74 09	